Jenny Deng spoke at the Weijie 2015 ANDA Seminar, June 18-19, 2015, Tianjin, China. The title of her presentation was “Patent Strategies in Generic Drug Development and Approval – Case Studies of ANDA Paragraph IV Challenges.” The conference is a China-US pharmaceutical industry summit designed for Chinese pharmaceutical companies. Ms. Deng covered the following topics: (1) Patent issues under the Hatch Waxman Act, (2) Patent strategies in ANDA drug development and approval, and (3) Case Studies – ANDA Paragraph IV litigations. Other speakers included former U.S. FDA officials and regulatory experts.